Alle verbonden artikelen

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Auteurs : Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC
Jaar : 2016
Journal : Anticancer Drugs
Volume : 27
Pagina's : 1021-7

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Auteurs : Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A
Jaar : 2016
Journal : Expert Opin Drug Metab Toxicol
Volume : 12(8)
Pagina's : 947-57

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Auteurs : Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart-Gebhart M, Gelber Rd
Jaar : 2016
Journal : Breast Cancer Res Treat
Volume : 155
Pagina's : 127-32

Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

Auteurs : Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, Von Minckwitz G, Buyse M, Piccart-Gebhart M
Jaar : 2016
Journal : Ann Oncol
Volume : 27(6)
Pagina's : 1029-34

Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Auteurs : Drisis S, Metens T, Ignatiadis M, Stathopoulos K, Chao SL, Lemort M
Jaar : 2016
Journal : Eur Radiol
Volume : 26(5)
Pagina's : 1474-84

Bladder and vaginal transitional cell carcinoma: A case report.

Auteurs : Aoun F, Kourie HR, El Rassy E, Van Velthoven R
Jaar : 2016
Journal : Oncol Lett
Volume : 12
Pagina's : 2181-2183

Checkpoint inhibitors: outstanding efficacy but at what cost?

Auteurs : Klastersky J
Jaar : 2016
Journal : Curr Opin Oncol
Volume : 28
Pagina's : 253

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Auteurs : Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K
Jaar : 2016
Journal : Oncoimmunology
Volume : 6
Pagina's : e1257452

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT0006

Auteurs : Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart-Gebhart M, Cameron D
Jaar : 2016
Journal : Eur J Cancer
Volume : 53
Pagina's : 144-54

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Auteurs : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Jaar : 2016
Journal : Ann Oncol
Volume : 27(4)
Pagina's : 619-24

What is the role of informed decision-making?

Auteurs : Pondé N, Dal Lago L, Azim HA Jr
Jaar : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(9)
Pagina's : 893

Frequent incidence of BARD1 truncating mutations in germline DNA from triple negative breast cancer patients.

Auteurs : De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart M, Pauwels I, Teugels E
Jaar : 2016
Journal : Clin. Genet.
Volume : 89(3)
Pagina's : 336-40.

Will Testicular Germ Cell Tumors Remain Untargetable?

Auteurs : Aoun F, Kourie HR, Albisinni S, Roumeguère T
Jaar : 2016
Journal : Target Oncol
Volume : 11(6)
Pagina's : 711-21

Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.

Auteurs : Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S
Jaar : 2016
Journal : Maturitas
Volume : 84
Pagina's : 81-8

70-Gene Signature in Early-Stage Breast Cancer.

Auteurs : van’t Veer LJ, Rutgers EJT, Piccart-Gebhart M
Jaar : 2016
Journal : N Engl J Med
Volume : 375
Pagina's : 2200-2201

Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design.

Auteurs : Kourie HR, Aoun F
Jaar : 2016
Journal : Invest New Drugs
Volume : 34(4)
Pagina's : 513-4

Biomarkers for adverse events associated with immune checkpoint inhibitors.

Auteurs : Kourie HR, Paesmans M, Klastersky J
Jaar : 2016
Journal : Biomark Med
Volume : 10
Pagina's : 1029-31

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Auteurs : Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S
Jaar : 2016
Journal : Clin Breast Cancer
Volume : 16(5)
Pagina's : 364-71

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Auteurs : Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S
Jaar : 2016
Journal : Nat Rev Clin Oncol
Volume : 13(4)
Pagina's : 228-41

Breast cancer in 2015: Academic research sheds light on issues that matter to patients.

Auteurs : Piccart-Gebhart M, Gingras I
Jaar : 2016
Journal : Nat Rev Clin Oncol
Volume : 13
Pagina's : 67-8